Wplyw suplementacji diety fruktanami i chromem[III] na stezenie glukozy i insuliny w krwi oraz beta-oksydacje w limfocytach szczurow z cukrzyca typu 1

• Autorzy: Krejpcio Z , Kuryl T. , Debski B. , Wojciak R.W.

Warianty tytułu

EN

Effect of dietary supplementation with fructans and chromium[III] on blood glucose and insulin and beta-oxidation in lymphocytes of type 1 diabetic rats

• Języki publikacji: PL

Abstrakty

EN

The 3-factorial study was designed to determine the effects of 5-week dietary supplementation with fructans (inulin or oligofructose, 5% or 10%) as well as a chromium(III) propionate complex (0.3 or 5 mg Cr/kg diet) on blood glucose and insulin, as well as β-oxidation of fatty acids in lymphocytes of STZ induced type 1 diabetic Wistar rats. Dietary inulin supplementation was more efficient in improving blood biochemistry vs. oligofructose. A high-fructan diet significantly lowered blood glucose, insulin resistance index (HOMA-R), and increased β-oxidation of fatty acids in lymphocytes of rats vs. low-fructan diet. Supplementary Cr(III) significantly decreased blood glucose, HOMA-R index and increased β-oxidation activity in lymphocytes of hyperglycemic rats. Moreover, many interaction effects between experimental factors influencing blood biochemical indices were found. The results suggest that dietary fructans and chromium(III) supplementation exerted beneficial effects on glucose and lipid metabolism, increasing the efficiency of their utilization in type 1 diabetic rats.

Słowa kluczowe

PL

szczury; limfocyty; zywienie zwierzat; zwierzeta chore; fruktany; cukrzyca typu 1; beta-oksydacja; poziom glukozy; badania krwi; poziom insuliny; dodatki paszowe; chrom trojwartosciowy

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2007
• Tom: 63
• Numer: 11 Supl.
• Strony: 1494-1496
• Opis fizyczny: s.1494-1496,tab.,bibliogr.

Twórcy

autor

Krejpcio Z

• Akademia Rolnicza w Poznaniu, ul.Wojska Polskiego 31, 60-624 Poznan

autor

Kuryl T.

autor

Debski B.

autor

Wojciak R.W.

Bibliografia

• 1. Anderson R. A.: Chromium as an essential nutrient for humans. Regul. Toxicol. Pharmacol. 1997, 26, 35-41.
• 2. Anderson R. A., Roussel A. M., Zouari N., Mahjoub S., Matheau J. M., Kerkeni A.: Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes mellitus. J. Am. Coll. Nutr. 2001, 2, 212-218.
• 3. Anon.: Scientific Committee on Food, European Food Safety Authority: Scientific Committee on Food. Tolerable upper intake levels for vitamins and minerals. Scientific panel on dietetic products, nutrition and allergies, European Food Safety Authority. 2006, 2, 261-271.
• 4. Appleton D. J., Rand J. S., Sunvold G. D., Priest J.: Dietary chromium tripicolinate supplementatiion reduces glucose concentration and improves glucose tolerance in normal-weight cats. J. Feline Med. Surg. 2002, 4, 13-25.
• 5. Cefalu W. T., Wang Z. Q., Zhang X. H., Baldor L. C., Russell J. C.: Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats. J. Nutr. 2002, 132, 1107-1114.
• 6. Cheng N., Zhu X., Shi H., Chi J., Anderson R.: Follow-up survey of people with type 2 diabetes mellitus consuming supplemental chromium. J. Trace Elem. Expt. Med. 1999, 12, 55-60.
• 7. Delzenne N. M., Kok N.: Effects of fructans-type prebiotics on lipid metabolism. Am. J. Clin. Nutr. 2001, 73, 456S-458S.
• 8. Dębski B., Zalewski W., Gralak M. A., Kosla T.: Chromium-yeast supplementation of chicken broilers in an industrial farming system. J. Trace Elem. Med. Biol. 2004, 18, 47-51.
• 9. Earnshaw A., Figgis B. N., Lewis J.: Chemistry of polynuclear compounds. Part VI. Magnetic properties of timer chromium and iron carboxylates. J. Chem. Soc. A. 1966, 5, 1656-1663.
• 10. Frame S., Zheleva D.: Targeting glycogen synthase kinase-3 in insulin signaling, Expert Opin. Ther. Targets. 2006, 10, 429-444.
• 11. Ghosh D., Bhattacharya B., Mukherjee B., Manna B., Sinha M., Chowdhury J., Chowdhury S.: Role of chromium supplementation in Indians with type 2 diabetes mellitus. J. Nutr. Biochem. 2002, 3, 690-697.
• 12. Jackson K. G., Taylor G. R., Clohessy A. M., Williams C. M.: The effect of the daily intake of inulin on fasting lipid, insulin and glucose concentrations in middle-aged men and women. Br. J. Nutr. 1999, 82, 23-30.
• 13. Kurył T., Adamowicz M., Dębski B., Bertrand J., Martynik K.: Degradation of [9,10] - 3H - myristic acid by lymphocytes. Screening test of inherited disorders of activation, transport and mitochondrial oxidation of fatty acids. Ateroskleroza. 2001, 5, 23-27.
• 14. Kurył T., Dębski B.: Is metabolism of fatty acids in broiler chicken affected by chromium? Ateroskleroza. 2001, 5, 132-133.
• 15. Kuryl T., Krejpcio Z., Wójciak R. W., Lipko M., Debski B., Staniek H.: Chromium(III) propionate and dietary fructans supplementation stimulate erythrocyte glucose uptake and beta-oxidation in lymphocytes of rats. Biol. Trace Elem. Res. 2006, 114, 237-248.
• 16. Letexier D., Diraison F., Beylot M.: Addition of inulin to a moderately high-carbohydrate diet reduces hepatic lipogenesis and plasma triacylglycelor concentrations in human. Am. J. Clin. Nutr. 2003, 73, 559-564.
• 17. Manning N. J., Olpin S. E., Pollitt R. J., Webley J.: A comparison of [9,10-3H] myristic acid for the detection of deffects of fatty acid oxidation in intact fibroblast. J. Inher. Metab. Dis. 1990, 13, 58-68.
• 18. McCarty M. F.: Nitric oxide deficiency, leukocyte activation, and resultant ischemia are crucial to the pathogenesis of diabetic retinopathy/neuropathy - preventive potential of antioxidants, essential fatty acids, chromium, ginkgolides, and pentoxifylline. Med. Hypotheses. 1998, 50, 435-449.
• 19. Morris B. W., Kouta S., Robinson R., MacNeil S., Heller S.: Chromium supplementation improves insulin resistance in patients with Type 2 diabetes mellitus. Diabet. Med. 2000, 17, 684-685.
• 20. Pechova A., Pavlata L., Illek J.: Metabolic effects of chromium administration to dairy cows in the period of stress. Czech J. Anim. Sci. 2002, 47, 1-7.
• 21. Reeves P. G., Nielsen H., Fahey G. C.: AIN-93 - Purified diets for laboratory rodents - final report of the American Institute of Nutrition ad hoc writing Committee on the Reformulation of the AIN-76 A rodent diet. J. Nutr. 1993, 123, 1939-1951.
• 22. Robertson L. A., Kim A. J., Werstuck G. H.: Mechanisms linking diabetes mellitus to the development of atherosclerosis: a role for endoplasmic reticulum stress and glycogen synthase kinase-3. Can. J. Physiol. Pharmacol. 2006, 84, 39-49.
• 23. Shinde U. A., Goyal R. K.: Effect of chromium picolinate on histological alterations in STZ and neonatal STZ diabetic rats. J. Cell Mol. Med. 2003, 7, 322-329.
• 24. Shinde U. A., Sharma G., Xu Y. J., Dhalla N. S., Goyal R. K.: Anti-diabetic activity and mechanism of action of chromium chloride, Exp. Clin. Endocrinol. Diabetes. 2004, 112, 248-252.
• 25. Vincent J. B.: Mechanisms of chromium action: low-molecular-weight chromium-binding substance. J. Am. Coll. Nutr. 1999, 18, 6-12.
• 26. Yamamoto A., Wada O., Manabe S.: Evidence that chromium is an essential factor for biological activity of low-molecular-weight, chromium-binding substance. Biochem. Biophys. Res. Commun. 1989, 63, 189-193.